AstraZeneca expects profit growth to pick up this year after the Covid-19 vaccine developer beat forecasts for quarterly drug sales, with demand for its cancer and other therapies cushioning the disruption caused by the pandemic.
Last year was a crucial one for the Anglo-Swedish company. It teamed up with the University of Oxford to develop a Covid-19 vaccine, and struck its largest ever deal by buying US drugmaker Alexion.
AstraZeneca said on Thursday it expects 2021 revenue to increase by a low-teens percentage, with “faster growth” in core earnings to $4.75 to $5.00 per share. That translates to 18-24 per cent growth in earnings, following 15 per cent in 2020.
The guidance was a little lower than the $5.10 per share analysts expect, according to Refinitiv Eikon data, but AstraZeneca shares rose 2 per cent in early trade.
Covid-19 vaccine
The London-listed company said its forecast did not include any impact from its Covid-19 vaccine, adding it would report sales of the shot separately from the first quarter of 2021. It has pledged not to profit from the vaccine during the pandemic.
Much is riding on the British-developed "vaccine for the world", since it is cheaper and can be distributed more easily than rivals from Pfizer/BioNTech and Moderna.
Pfizer last week said it expects $15 billion in sales from its vaccine this year.
"With positive recommendations or approvals (for the vaccine) now received in over 50 countries . . . we're already helping to change the course of the pandemic," AstraZeneca chief executive Pascal Soriot said in a video.
While public interest is largely on the vaccine, AstraZeneca’s core business for diabetes, heart and kidney, and cancer medicines has proved resilient.
Fourth-quarter product sales, which exclude payments from tie-ups, surpassed a company-compiled consensus. Core profit of $1.07 per share for the three months ended December 31st was in line with estimates.
Sales from AstraZeneca’s best-selling drug Tagrisso soared 31 per cent, slightly above expectations.
"The company is arguably the poster child for big pharma turnarounds," said Third Bridge senior analyst Sebastian Skeet. – Reuters
